Results 111 to 120 of about 28,270 (206)

Consolidation of P2Y12 Testing While Maintaining Quality and Turnaround Time [PDF]

, 2017
Objective: To consolidate the test performed at 2 different locations at 1, thereby improving cost effectiveness while maintaining quality and result turnaround time.https://jdc.jefferson.edu/patientsafetyposters/1059/thumbnail ...
Gong, MD, Jerald Z., Jagannathan, MBBS, Geetha   +1 more
core   +1 more source

Ticagrelor versus clopidogrel in the management of acute myocardial infarction

Journal of Community Hospital Internal Medicine Perspectives, 2019
Hypothesis: In the care of acute myocardial infarction, ticagrelor attenuates post-ischemic myocardial damage and inhibits platelet activity to a greater extent than clopidogrel.
Candice Volney, Anthony Collins, Sarah Adams   +2 more
doaj   +1 more source

Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis

Drug Design, Development and Therapy, 2016
Michael R Preusch,1 Jonas Rusnak,1 Kathrin Staudacher,2 Carolin Mogler,3 Lorenz Uhlmann,4 Philipp Sievers,1 Florian Bea,1 Hugo A Katus,1 Erwin Blessing,1 Ingo Staudacher1 1Department of Internal Medicine III, 2Department of Neonatology, 3Department of ...
Preusch MR, Rusnak J, Staudacher K, Mogler C, Uhlmann L, Sievers P, Bea F, Katus HA, Blessing E, Staudacher I   +9 more
doaj  

Investigação recente em antitrombóticos. Novidades para o tratamento dos doentes com síndromas coronárias agudas [PDF]

, 2010
A terapêutica antitrombótica ocupa um lugar central no tratamento da doença coronária aguda. A sua importância foi reforçada com a generalização dos procedimentos de intervenção percutânea, em especial quando são implantados dispositivos intra-coronários.
Morais, João
core  

Antiplatelet and anticoagulant therapy for non-ST-elevation acute coronary syndromes in a general hospital [PDF]

, 2014
Aim: To audit compliance with the 2011 European Society of Cardiology (ESC) guidelines for prescribing antiplatelet and anticoagulant therapy in patients diagnosed with non-ST-elevation acute coronary syndromes (NSTE-ACS).
Mason, Giorgia, Wirth, Francesca, Cignarella, Andrea, Xuereb, Robert G., Azzopardi, Lilian M.   +4 more
core   +1 more source

Single Antiplatelet Therapy With Ticagrelor in Flow-Diversion Treatment of Ruptured Dissecting Cerebral Pseudoaneurysms: A Meta-Analysis. [PDF]

Cureus
Alqahtani SA, AlQahatani S.
europepmc   +1 more source

Therapeutic Plasma Exchange for Uncontrollable Bleeding After Platelet Inhibition with Ticagrelor: A Report of 2 Cases. [PDF]

Am J Case Rep
Herrmann A, Mai B, Bai Y, Castillo B, Kar B, Klein K, Salas de Armas IA, Salazar E, Tint H, Gregoric ID.   +9 more
europepmc   +1 more source

Dual antiplatelet therapy in acute ischemic stroke: Does diabetes mellitus define a target population? [PDF]

Neurotherapeutics
Nedelcu S.
europepmc   +1 more source

Real-World Antiplatelet Use and Clinical Outcomes in Patients with Advanced Chronic Kidney Disease Following Acute Coronary Syndrome: A Descriptive Cohort Study. [PDF]

J Clin Med
Alfehaid L, Alzahrani E, Alsubaie A, Almutairi M, Alomran M, Alghadeer S.   +5 more
europepmc   +1 more source

Single-Site Experience in the ONSET-OFFSET Study Demonstrates Pharmacodynamic and Pharmacokinetic Advantages of Ticagrelor over Clopidogrel in Patients with Chronic Coronary Syndromes. [PDF]

J Cardiovasc Dev Dis
Judge HM, Parker WAE, Storey RF.
europepmc   +1 more source